Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2025-05-07 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于公司持股 5%以上股东减持股份的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding a shareholder holding more than 5% of the company's shares planning to reduce their holdings. It details the shareholder's name, shareholding percentage, planned reduction amount, method, timing, and related regulatory compliance. The content focuses on a major shareholding notification about a reduction in stake by a significant shareholder. It does not contain financial statements, earnings data, or management discussion. The document length is 2221 characters, which is relatively short and typical for a shareholding notification. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2025-05-07 Chinese
第五届董事会第十六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 16th meeting of the 5th Board of Directors of Ruikang Pharmaceutical Group Co., Ltd. It details the approval of a proposal to authorize the Board to issue shares via a simplified procedure to specific targets, including voting results and references to related announcements. The document is short (1059 characters) and serves as a formal notice of board decisions rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2025-05-06 Chinese
关于增加2024年年度股东大会临时提案的补充通知
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the 2024 Annual General Meeting (AGM) of 瑞康医药集团股份有限公司, including information about the addition of a temporary proposal, meeting logistics, voting procedures, and proxy forms. It references the 2024 Annual Report and other reports to be discussed at the AGM but does not contain the reports themselves. The document is over 5,000 characters and is not a brief notice of report publication but a comprehensive AGM notification and supplementary notice. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including notices and proposals for shareholder meetings.
2025-05-06 Chinese
关于提请股东大会授权董事会以简易程序向特定对象发行股票的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from 瑞康医药集团股份有限公司 regarding a proposal to the shareholders' meeting to authorize the board of directors to issue shares to specific investors via a simplified procedure. It details the authorization scope, issuance conditions, pricing, lock-up periods, and procedural authorizations. The document is an announcement of a planned capital raising activity through a private placement of shares, requesting shareholder approval. It does not contain actual financial statements or results but rather outlines the proposed financing plan and seeks shareholder authorization. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 4600 characters, which is consistent with an announcement rather than a full report. Hence, the classification is CAP with high confidence.
2025-05-06 Chinese
第五届监事会第十五次会议决议的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of a resolution passed at the 15th meeting of the 5th Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. It details the approval of a proposal to authorize the board to issue shares via a simplified procedure to specific investors, with a financing cap and authorization period specified. The document includes voting results and references compliance with relevant securities issuance regulations. It is an announcement of a board resolution related to capital raising activities, not the actual issuance or detailed financing report. The document length is short (872 characters), and it is an announcement of a decision rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2025-05-06 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '瑞康医药集团股份有限公司2025 年第一季度报告' which translates to 'Ruikang Pharmaceutical Group Co., Ltd. 2025 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and shareholder information for the first quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It also mentions that the report is unaudited. Given the detailed quarterly financial data and the reporting period being a quarter, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.